FDA declines to approve Satsuma’s migraine treatment STS101
The US FDA has declined to grant approval for Satsuma Pharmaceuticals’ STS101 for acute migraine treatment in adults.
The US FDA has declined to grant approval for Satsuma Pharmaceuticals’ STS101 for acute migraine treatment in adults.
What's Your Reaction?
